A Novel Activatable Nanoradiosensitizer for Second Near‐Infrared Fluorescence Imaging‐Guided Safe‐Dose Synergetic Chemo‐Radiotherapy of Rheumatoid Arthritis

• DOI: 10.1002/advs.202308905
• Publication Date: 2024-02-29T06:29:55Z
• Authors: Yarong Jin; Dongsheng Li; Xiaochun Zheng; Mengting Gao; Wenxuan Wang; Xin Zhang; Weiwei Kang; Chongqing Zhang; Shutong Wu; Rong Dai; Ziliang Zheng; Ruiping Zhang
• Keywords: Indocyanine Green; Fluorescence-lifetime imaging microscopy

Abstract The precise theranostics of rheumatoid arthritis (RA) remains a formidable challenge in clinical practice. Exploring novel applications contemporary therapeutic approaches like chemo‐radiotherapy is promising as highly effective strategy for RA. Herein, activatable nanoradiosensitizer‐40 (denoted IRnR‐40) developed, based on encapsulating the clinically approved drugs cisplatin (DDP) and indocyanine green (ICG) within gelatin shell to achieve second near‐infrared fluorescence (NIR‐II FL) imaging‐guided safe‐dose synergetic chemo‐radiotherapy. high concentration matrix metalloproteinase‐9 (MMP‐9) RA microenvironment plays pivotal role triggering responsive degradation IRnR‐40, leading rapid release functional molecules DDP ICG. released ICG serves dual purpose illuminating inflamed joints facilitate accurate target volume delineation guiding radiotherapy, well acting real‐time reporter quantifying monitor efficacy. Meanwhile, achieves synergistic chemotherapy radiosensitization via reactive oxygen species (ROS)‐mediated mitochondrial apoptotic pathway. To sum up, this nanoradiosensitizer IRnR‐40 believed be first attempt efficient NIR‐II FL RA, which provides new paradigm refractory benign diseases.